Table 1.
Basic characteristics of patients with AAV and comparison between different genders.
| Total (N = 84) | Group | |||
|---|---|---|---|---|
| Male (N = 51) | Female (N = 33) | P-value | ||
| Age (Y) | 56.6 ± 13.5 | 57.9 ± 10.5 | 52.2 ± 16.7 | 0.005* |
| Disease duration (M) | 5.0 ± 7.1 | 3.3 ± 5.1 | 7.5 ± 8.8 | 0.008* |
| Mortality rate ( n , %) | ||||
| 3-month | 4 (4.8) | 4 (7.8) | 0 (0) | 0.105 |
| 6-month | 12 (14.3) | 10 (19.6) | 2 (6.1) | 0.056 |
| 12-month | 14 (16.7) | 12 (23.5) | 2 (6.1) | 0.024* |
| Classification of diseases ( n , %) | ||||
| GPA | 8 (9.5) | 5 (9.8) | 3 (9.1) | 0.913 |
| MPA | 72 (85.7) | 42 (82.4) | 30 (90.9) | 0.118 |
| EGPA | 4 (4.8) | 4 (7.8) | 0 (0) | 0.042* |
| Types of ANCA ( n , %) | ||||
| p-ANCA | 58 (69) | 31 (60.8) | 27 (81.8) | 0.227 |
| c-ANCA | 6 (7.1) | 4 (7.8) | 2 (6.1) | 0.596 |
| MPO | 74 (88.1) | 46 (90.2) | 28 (84.8) | 0.311 |
| PR3 | 11 (13.3) | 8 (15.7) | 3 (9.1) | 0.353 |
| Organ involvement ( n , %) | ||||
| Lung | 42 (50) | 28 (54.9) | 14 (42.4) | 0.264 |
| Kidney | 38 (45.2) | 20 (39.2) | 18 (54.5) | 0.168 |
| Skin | 4 (4.8) | 2 (3.8) | 2 (6.1) | 0.657 |
| Mucosa and eye | 1 (1.2) | 1 (2.0) | 0 (0) | 0.316 |
| Ear, nose, throat | 6 (7.1) | 4 (7.8) | 2 (6.1) | 0.754 |
| Cardiovascular | 1 (1.2) | 0 (0.0) | 1 (3.0) | 0.170 |
| Nervous system | 4 (4.8) | 2 (3.9) | 2 (6.1) | 0.657 |
| Joint and muscle | 27 (32.1) | 16 (31.4) | 11 (33.3) | 0.851 |
| Non-specific symptoms | 63 (75) | 35 (68.6) | 28 (84.8) | 0.094 |
| Lab data (median, IQR) | ||||
| WBC (109/L) | 9.3 [6.0–10.8] | 10.2 [6.6–12.8] | 8.0 [5.2–10.2] | 0.044* |
| HB (g/l) | 86 [72.3–96.5] | 88 [76–98] | 81.9 [69–89.5] | 0.046* |
| PLT (109/L) | 278.7 [181–351] | 280.4 [198–351] | 276.2 [177–339] | 0.689 |
| N (109/L) | 7.4 [4.2–9.1] | 8.2 [4.5–10.2] | 6.2 [3.3–8.5] | 0.048* |
| L (109/L) | 1.3 [0.9–1.6] | 1.3 [0.9–1.7] | 1.2 [0.8–1.5] | 0.513 |
| NLR | 7.2 [3.0–5.5] | 7.5 [3.6–8.8] | 6.7 [2.7–8.8] | 0.165 |
| PLR | 266.7 [144.3–347.5] | 254.4 [141.0–345.9] | 285.6 [149.8–382.6] | 0.724 |
| MPV (fL) | 10.3 [9.4–11.0] | 10.4 [9.4–11.1] | 10.2 [9.5–11.0] | 0.706 |
| RDW-CV (%) | 14.4 [12.9–15.6] | 14.3 [12.7–15.5] | 14.6 [13.2–15.6] | 0.463 |
| RDW-SD (fL) | 45.9 [41.7–49.0] | 45.8 [41.7–49.0] | 45.9 [41.3-49.2] | 0.818 |
| ESR (mm/h) | 69.1 [34–99.5] | 77.2 [56–101.3] | 56.8 [26–93.8] | 0.03* |
| CRP (mg/l) | 46.3 [6.49–69.3] | 55.4 [8.4–84.6] | 27.5 [26–46] | 0.019* |
| C3 (g/l) | 0.9 [0.7–1.0] | 0.8 [0.7–1.0] | 0.9 [0.9–1.0] | 0.781 |
| C4 (g/l) | 0.2 [0.2-0.3] | 0.2 [0.2–0.3] | 0.2 [0.2–0.3] | 0.735 |
| AL (u/l) | 22.7 [7.7-26.6] | 27.0 [10.6–27.3] | 15.7 [5.2–18.8] | 0.013* |
| ALB (g/l) | 29.3 [25–33.7] | 28.2 [10.6–27.2] | 31.1 [26.8–30.9] | 0.016* |
| GLB (g/l) | 31.5 [25.9–36.7] | 31.4 [26.8–37.4] | 31.7 [25.3–36.6] | 0.848 |
| TB (umol/l) | 7.1 [4.3–8.3] | 7.3 [4.1–9.1] | 6.8 [4.3–8.2] | 0.907 |
| Scr (umol/l) | 378.7 [126.2-528.2] | 402.7 [196.6–389.9] | 343.1 [80.5–559.8] | 0.152 |
| BUN (mmol/l) | 17.5 [9.1–23.9] | 20.0 [10.7–28.9] | 13.6 [6.4–18.0] | 0.013* |
| UA (ummol/l) | 396.5 [300.2–483] | 418.1 [330.1–517.7] | 363.3 [239.4–454.9] | 0.069 |
| Hematuria (n, %) | 76 (90.5) | 45 (88.2) | 31 (93.9) | 0.518 |
| Proteinuria (n, %) | 65 (77.4) | 40 (78.4) | 25 (75.8) | 0.559 |
| BVAS | 12 [9.5-−14.5] | 12 [10–15] | 10 [9-12.75] | 0.008* |
| Treatment after diagnosis ( n , %) | ||||
| Different doses of GC | ||||
| <0.5 mg/kg | 2 (2.4) | 2 (3.9) | 0 (0) | 0.149 |
| 0.5–1 mg/kg | 23 (27.4) | 16 (31.4) | 7 (21.2) | 0.267 |
| >1 kg/mg | 55 (65.5) | 30 (58.8) | 25 (75.8) | 0.140 |
| CTX | 54 (64.3) | 34 (66.7) | 20 (60.6) | 0.571 |
| MMF | 8 (9.5) | 1 (2.0) | 7 (21.2) | 0.079 |
| Plasma exchange | 22 (26.2) | 12 (23.5) | 10 (30.3) | 0.490 |
| CD20 monoclonal antibody | 2 (2.4) | 1 (2.0) | 1 (3.3) | 0.756 |
| Single drug or combination drugs | ||||
| 1 drug | 18 (21.4) | 11 (21.6) | 7 (21.2) | 0.969 |
| 2 drugs | 41 (48.8) | 24 (47.1) | 17 (51.5) | 0.690 |
| 3 drugs | 14 (16.7) | 7 (13.7) | 7 (21.2) | 0.369 |
| ≥4 drugs | 11 (13.1) | 9 (17.6) | 2 (6.1) | 0.107 |
Y, years; M, months; %, percentage; GPA, Granulomatous vasculitis; MPA, Microscopic vasculitis; EGPA, Eosinophilic granulomatous polyangiitis; c-ANCA, Cytoplasmic anti-neutrophil cytoplasmic antibody; p-ANCA, Perinuclear anti-neutrophilic cytoplasmic antibody; PR3, Protease 3; MPO, Myeloperoxidase; IQR, Interquartile range; WBC, White blood cell; HB, Hemoglobin; PLT, Platelet; N, Neutrophils; L, Lymphocytes; NLR, Neutrophil-lymphocyte ratio; PLR, Platelet lymphocyte ratio; MPV, Mean platelet volume; RDW-CV, Red blood cell volume width-variation of red blood cells; RDW-SD, Red blood cell volume distribution width-standard deviation; ESR, Erythrocyte sedimentation; CRP, C-reactive protein; C3, Complement 3; C4, Complement 4; ALT, Glutamic-pyruvic transaminase; sALB, Albumin; GLO, Globulin; TBIL, Total bilirubin; BUN, Urea nitrogen; Scr, Serum creatinine; UA, Uric acid; BVAS, Birmingham Vasculitis Activity Score; GC, Glucocorticoid; CTX, Cyclophosphamide; MMF, Mycophenolate mofetil.
P < 0.05.